Gateway® pDONR™ Vectors

Catalog numbers 12536-017 and 12535-035

Revision Date 29 March 2012
Publication Part number 25-0531
# Contents

Kit Contents and Storage ........................................................................................ iv

**Introduction** ........................................................................................................ 1

Overview ................................................................................................................. 1

**Methods** ............................................................................................................ 3

General Guidelines ................................................................................................. 3

Perform the BP Reaction .......................................................................................... 5

Transform Competent Cells ...................................................................................... 8

Analyze Entry Clones ............................................................................................... 10

**Appendix** ............................................................................................................ 12

Recipes ...................................................................................................................... 12

Zeocin™ Selective Antibiotic ................................................................................... 13

Map and Features of pDONR™ 221 and pDONR™/Zeo ........................................ 14

Accessory Products .................................................................................................. 16

Technical Support .................................................................................................... 17

Gateway® Clone Distribution Policy ......................................................................... 21

References ................................................................................................................. 22
This manual is supplied with the following vectors:

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pDONR™221</td>
<td>12536-017</td>
</tr>
<tr>
<td>pDONR™/Zeo</td>
<td>12535-035</td>
</tr>
</tbody>
</table>

**Gateway® pDONR™ Vectors**

**Shipping and Storage**

pDONR™221 is shipped at room temperature. Upon receipt, store at −30°C to −10°C.

pDONR™/Zeo is shipped on blue ice. Upon receipt, store the pDONR™/Zeo vector at −30°C to −10°C and the Zeocin™ selective antibiotic at −30°C to −10°C, protected from light.

**Contents**

6 μg pDONR™ vector, supplied at 150 ng/μL in TE buffer, pH 8.0, in a total volume of 40 μL.

pDONR™/Zeo is also supplied with 1.25 mL Zeocin™ selective antibiotic. Zeocin™ selective antibiotic is provided as a 100 mg/mL solution in deionized, sterile water.

**Product Use**

For research use only. Not intended for any animal or human therapeutic or diagnostic use.
Introduction

Overview

Description

pDONR™ vectors are Gateway®-adapted vectors designed to generate attL-flanked entry clones containing your gene of interest following recombination with an attB expression clone or an attB PCR product. After creating an entry clone, your gene of interest may then be easily shuttled into a large selection of expression vectors using the Gateway® LR recombination reaction. Refer to the following table for a list of the available pDONR™ vectors.

<table>
<thead>
<tr>
<th>Vector</th>
<th>M13 Sequencing Sites</th>
<th>Selection Marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>pDONR™221</td>
<td>Yes</td>
<td>Kanamycin</td>
</tr>
<tr>
<td>pDONR™/Zeo</td>
<td>Yes</td>
<td>Zeocin™</td>
</tr>
</tbody>
</table>

Features

The pDONR™ vectors contain the following elements:

- rrrB T1 and T2 transcription terminators for protection of the cloned gene from expression by vector-encoded promoters
- M13 Forward (−20) and M13 Reverse priming sites for sequencing of the insert (pDONR™/Zeo only)
- Two recombination sites, attP1 and attP2, for recombinational cloning of the gene of interest from a Gateway® expression clone or attB PCR product
- ccdB gene located between the two attP sites for negative selection
- Chloramphenicol resistance gene located between the two attP sites for counterselection
- Kanamycin or Zeocin™ resistance gene for selection in E. coli (see the preceding table)
- pUC origin for replication and maintenance of the plasmid in E. coli.

For a map of pDONR™221 and pDONR™/Zeo, see page 14.

Continued on next page
The Gateway® Technology

The Gateway® Technology is a universal cloning method that takes advantage of the site-specific recombination properties of bacteriophage lambda (Landy, 1989) to provide a rapid and highly efficient way to move your gene of interest into multiple vector systems. To express your gene of interest using Gateway® Technology, simply:

1. Generate an entry clone by performing a BP recombination reaction between a pDONR™ vector (e.g. pDONR™221) and an attB PCR product or expression clone.

2. Generate the desired expression clone by performing an LR recombination reaction between the entry clone and a Gateway® destination vector of choice.

3. Introduce your expression clone into the system of choice for expression of your gene of interest.

For more information on the Gateway® Technology, refer to the Gateway® Technology with Clonase® II manual, which is available from www.lifetechnologies.com/manuals or by contacting Technical Support (page 17).

attP sequence variations

The attP sites between the pDONR™ vectors will contain slight sequence variations which do not affect the specificity of recombination. Wild-type attP sites were modified to create the first-generation attP sites found in pDONR™201. First-generation sites were further modified to improve recombination efficiency and resulted in the second-generation attP sites found in pDONR™221 and pDONR™/Zeo.

For more information on characteristics of att sites, refer to the Gateway® Technology with Clonase® II manual.
Methods

General Guidelines

Introduction
You will perform a BP recombination reaction to transfer the gene of interest in an attB expression clone or attB PCR product to a donor vector to create an entry clone. To ensure that you obtain the best possible results, we suggest that you read this section and the one entitled Perform the BP Recombination Reaction (pages 5–9) before beginning.

Note
If you intend to go directly from an attB PCR product or attB expression clone into a destination vector without purifying the intermediate entry clone, refer to the Gateway® Technology with Clonase® II manual for a one-tube protocol.

Although this protocol allows you to generate expression clones more rapidly than the standard BP reaction followed by the LR reaction, fewer expression clones will be obtained (generally 10–20% of the total number of entry clones).

Propagate pDONR™ Vectors
If you intend to propagate and maintain the pDONR™ vectors, we recommend using One Shot® ccdB Survival 2 T1R Chemically Competent E. coli (page 16) for transformation. The ccdB Survival 2 T1R E. coli strain is resistant to CcdB effects and can support the propagation of plasmids containing the ccdB gene.

Note: Do not use general E. coli cloning strains including TOP10 or DH5α™ for propagation and maintenance as these strains are sensitive to CcdB effects.

Continued on next page
General Guidelines, Continued

Important

For optimal efficiency, perform the BP recombination reaction using:

- **Linear** \textit{att}B substrates (see the following guidelines to linearize \textit{att}B expression clones)
- **Supercoiled** \textit{att}P-containing pDONR™ vector

\textbf{Note}: Supercoiled or relaxed \textit{att}B substrates may be used, but will react less efficiently than linear \textit{att}B substrates.

Linearize Expression Clones

If you intend to perform a BP recombination reaction using an \textit{att}B expression clone, we recommend that you linearize the expression clone using a suitable restriction enzyme (see the following recommendations).

1. Linearize 1–2 μg of the expression clone with a unique restriction enzyme that does not digest within the gene of interest and is located outside the \textit{att}B region.
2. Ethanol precipitate the DNA after digestion by adding 0.1 volume of 3 M sodium acetate followed by 2.5 volumes of 100% ethanol.
3. Pellet the DNA by centrifugation. Wash the pellet twice with 70% ethanol.
4. Dissolve the DNA in 1X TE Buffer, pH 8.0 to a final concentration of 50–150 ng/μL.

If you intend to perform a BP recombination reaction using an \textit{att}B PCR product, we recommend purifying the PCR product to remove \textit{att}B primers and any \textit{att}B primer-dimers. These primers and primer-dimers can recombine efficiently with the pDONR™ vector in the BP reaction and may increase background after transformation into \textit{E. coli}. Refer to the Gateway® Technology with Clonase® II manual for a purification protocol using PEG/MgCl₂ precipitation.

\textbf{Note}: Standard PCR product purification protocols using phenol/chloroform extraction followed by sodium acetate and ethanol or isopropanol precipitation are not recommended for use in purifying \textit{att}B PCR products. These protocols generally have exclusion limits less than 100 bp and do not efficiently remove large primer-dimer products.

4
Perform the BP Reaction

Positive Control

pEXP7-tet is provided as a positive control for the BP reaction. pEXP7-tet is an approximately 1.4-kb linear fragment and contains attB sites flanking the tetracycline resistance gene and its promoter (Tc'). Using the pEXP7-tet fragment in a BP reaction with a donor vector results in entry clones that express the tetracycline resistance gene. The efficiency of the BP recombination reaction can easily be determined by streaking entry clones onto LB plates containing 20 μg/mL tetracycline.

Gateway® BP Clonase® II Enzyme Mix

Gateway® BP Clonase® II enzyme mix (page 16) combines the proprietary enzyme formulation and 5X BP Reaction Buffer previously supplied as separate components in Gateway® BP Clonase® enzyme mix into an optimized single tube format to allow easier set-up of the BP recombination reaction. Use the protocol provided in this section to perform the BP recombination reaction using Gateway® BP Clonase® II enzyme mix.

Note: You may perform the BP recombination reaction using Gateway® BP Clonase® enzyme mix, if desired. To use Gateway® BP Clonase® enzyme mix, follow the protocol provided with the product. Do not use the protocol for Gateway® BP Clonase® II enzyme mix provided on page 7.

Determine how much attB DNA and donor vector to use in the reaction

For optimal efficiency, we recommend using the following amounts of attB PCR product (or linearized attB expression clone) and donor vector in a 10 μL BP recombination reaction with Gateway® BP Clonase® II enzyme mix:

- An equimolar amount of attB PCR product (or linearized attB expression clone) and the donor vector
- 50 femtomoles (fmol) each of attB PCR product (or linearized attB expression clone) and donor vector is preferred, but the amount of attB PCR product used may range from 20–50 fmol
  
  Note: 50 fmol of donor vector) is approximately 150 ng

- For large PCR products (>4 kb), use at least 50 fmol of attB PCR product, but no more than 250 ng

For a formula to convert fmol of DNA to nanograms (ng), see Convert femtomoles (fmol) to nanograms (ng). For an example, see page 6.

Continued on next page
Perform the BP Reaction, Continued

- Do not use more than 250 ng of donor vector in a 10 μL BP reaction because this will affect the efficiency of the reaction.
- Do not exceed more than 0.5 μg of total DNA (donor vector plus attB PCR product) in a 10 μL BP reaction because excess DNA will inhibit the reaction.

Convert femtomoles (fmol) to nanograms (ng)

Use the following formula to convert femtomoles (fmol) of DNA to nanograms (ng) of DNA where N is the size of the DNA in bp.

\[ \text{ng} = (\text{fmol})(N)\left(\frac{660 \text{ fg}}{\text{fmol}}\right)\left(\frac{1 \text{ ng}}{10^6 \text{ fg}}\right) \]

Example of fmol to ng conversion

In this example, you need to use 50 fmol of an attB PCR product in the BP reaction. The attB PCR product is 2.5 kb in size. Calculate the amount of attB PCR product required for the reaction (in ng) by using the equation above:

\[(50 \text{ fmol})(2500 \text{ bp})\left(\frac{660 \text{ fg}}{\text{fmol}}\right)\left(\frac{1 \text{ ng}}{10^6 \text{ fg}}\right) = 82.5 \text{ ng of PCR product} \]

Required materials

- attB PCR product or linearized attB expression clone (see page 5 to determine the amount of DNA to use)
- Gateway® BP Clonase® II enzyme mix (see page 16 for ordering information; keep at −20°C until immediately before use)
- TE Buffer, pH 8.0 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
- 2 μg/μL Proteinase K solution (supplied with the Gateway® BP Clonase® II enzyme mix; thaw and keep on ice until use)
- pEXP7-tet positive control (50 ng/μL; supplied with the Gateway® BP Clonase® II enzyme mix)

Components supplied with the kit:

- pDONR™ vector (150 ng/μL)

Continued on next page
**Perform the BP Reaction, Continued**

**Perform the BP Reaction**

1. Add the following components to 1.5-mL microcentrifuge tubes at room temperature and mix.

<table>
<thead>
<tr>
<th>Components</th>
<th>Sample</th>
<th>Positive Control</th>
<th>Negative Control</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>attB</em> PCR product or linearized <em>attB</em> expression clone (20–50 fmol)</td>
<td>1–7 μL</td>
<td>—</td>
<td>1–7 μL</td>
</tr>
<tr>
<td>pDONR™ vector (150 ng/μL)</td>
<td>1 μL</td>
<td>1 μL</td>
<td>1 μL</td>
</tr>
<tr>
<td>pEXP7-tet positive control (50 ng/μL)</td>
<td>—</td>
<td>2 μL</td>
<td>—</td>
</tr>
<tr>
<td>TE Buffer, pH 8.0</td>
<td>to 8 μL</td>
<td>5 μL</td>
<td>to 10 μL</td>
</tr>
</tbody>
</table>

2. Remove the Gateway® BP Clonase® II enzyme mix and thaw on ice (~ 2 minutes).

3. Vortex the Gateway® BP Clonase® II enzyme mix briefly twice (2 seconds each time).

4. Add 2 μL of Gateway® BP Clonase® II enzyme mix to the sample and positive control. **Do not** add Gateway® BP Clonase® II enzyme mix to the negative control. Mix well by vortexing briefly twice (2 seconds each time).

**Reminder:** Return Gateway® BP Clonase® II enzyme mix to −20°C immediately after use.

5. Incubate reactions at 25°C for 1 hour.

**Note:** For most applications, a 1-hour incubation will yield a sufficient number of entry clones. Depending on your needs, the length of the recombination reaction can be extended up to 18 hours. An overnight incubation typically yields 5–10 times more colonies than a 1-hour incubation. For large PCR products (≥5 kb), longer incubations (i.e. overnight incubation) will increase the yield of colonies and are recommended.

6. Add 1 μL of the Proteinase K solution to each reaction. Incubate for 10 minutes at 37°C.


**Note:** You may store the BP reaction at −20°C for up to 1 week before transformation.
Transform Competent Cells

Introduction

After performing the BP recombination reaction, you will transform competent *E. coli* and select for entry clones using the appropriate antibiotic. General guidelines for transforming competent cells are provided in this section.

*E. coli* host strain

You may use any *recA, endA* *E. coli* strain including TOP10, OmniMAX™ 2-T1® or equivalent for transformation. **Do not** use *E. coli* strains that contain the F' episome (e.g. TOP10F'). These strains contain the *ccdA* gene and will prevent negative selection with the *ccdB* gene.

Selection media

Refer to the following table for the appropriate selection medium to use to select for entry clones. You will need 2 LB plates containing the appropriate antibiotic for each transformation. Pre-warm plates at 37°C for 30 minutes.

If you are using pDONR™/Zeo, you will need to use Low Salt LB agar for selection (see the following Note).

<table>
<thead>
<tr>
<th>Donor Vector</th>
<th>Selection Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>pDONR™221</td>
<td>LB + 50 μg/mL Kanamycin</td>
</tr>
<tr>
<td>pDONR™/Zeo</td>
<td>Low Salt LB + 50 μg/mL Zeocin™ selective antibiotic (see Note below)</td>
</tr>
</tbody>
</table>

The Zeocin™ resistance gene in pDONR™/Zeo allows selection of *E. coli* transformants using Zeocin™ antibiotic. For selection, use Low Salt LB agar plates containing 50 μg/mL Zeocin™ (see page 12 for a recipe). Note that for Zeocin™ to be active, the salt concentration of the bacterial medium must remain low (<90 mM) and the pH must be 7.5. For more information on storing and handling Zeocin™, refer to page 13.

**Note**

Continued on next page
Transform Competent Cells, Continued

Transform competent cells
Transform 1 µL of the BP recombination reaction into a suitable *E. coli* host (follow the manufacturer’s instructions) and select for entry clones using the appropriate antibiotic. We recommend plating 2 different volumes to ensure that at least 1 plate has well-spaced colonies.

What you should see
If you use *E. coli* cells with a transformation efficiency of $1 \times 10^8$ cfu/µg, the BP reaction should give you $>1500$ colonies if the entire BP reaction is transformed and plated.

Verify pEXP7-tet entry clones
If you included the pEXP7-tet control in your BP reaction, the efficiency of the BP reaction may be assessed by streaking the kanamycin-resistant colonies onto LB agar plates containing 20 µg/mL tetracycline. True entry clones should be tetracycline-resistant.
Analyze Entry Clones

**Analyze positive clones**

1. Pick 5 colonies and culture them overnight in LB medium containing the appropriate antibiotic.

2. Isolate plasmid DNA using your method of choice. We recommend using the PureLink® HQ Mini Plasmid Purification Kit (page 16).

3. Analyze the entry clones by restriction analysis to confirm the presence and correct orientation of the insert. Use a restriction enzyme or a combination of enzymes that cut once in the vector and once in the insert.

**Analyze transformants by PCR**

You may also analyze positive transformants using PCR. Use a primer that hybridizes within the vector (see page 11 for suggested primer sequences) and one that hybridizes within your insert. You will have to determine the amplification conditions. If you are using this technique for the first time, you may want to perform restriction analysis in parallel. Artifacts may be obtained because of mispriming or contaminating template. The protocol below is provided for your convenience. Other protocols are suitable.

**Materials Needed:**
- PCR SuperMix High Fidelity (page 16)
- Appropriate forward and reverse PCR primers, 20 μM each (see page 11 for suggested primer sequences)

**Protocol:**
1. For each sample, aliquot 48 μL of PCR SuperMix High Fidelity into a 0.5-mL microcentrifuge tube. Add 1 μL each of the forward and reverse PCR primer.

2. Pick 5 colonies and resuspend them individually in 50 μL of the PCR SuperMix containing primers (remember to make a patch plate to preserve the colonies for further analysis).

3. Incubate the reaction for 10 minutes at 94°C to lyse cells and inactivate nucleases.


5. For the final extension, incubate at 72°C for 10 minutes. Store at 4°C.

6. Visualize by agarose gel electrophoresis.

*Continued on next page*
Analyze Entry Clones, Continued

**Recommended Primers**

We recommend using the following primers to analyze entry clones. Refer to the following diagram or on page 11 for the location of the primer binding sites.

<table>
<thead>
<tr>
<th><strong>pDONR™221 and pDONR™/Zeo</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>M13 Forward (−20) primer</td>
<td>5′-GTAAACGACGGCCAG-3′</td>
</tr>
<tr>
<td>M13 Reverse primer</td>
<td>5′-CAGGAAACAGCTATGAC-3′</td>
</tr>
</tbody>
</table>

**Recombination region of pDONR™ 221 and pDONR™/Zeo**

The recombination region of the expression clone resulting from pDONR™221 × entry clone or pDONR™/Zeo × entry clone is shown in the following figure.

**Features of the Recombination Region:**

- Shaded regions correspond to DNA sequences transferred from the attB substrate into pDONR™221 or pDONR™/Zeo by recombination. Non-shaded regions are derived from the pDONR™221 or pDONR™/Zeo vector.
- Bases 651 and 2897 of the pDONR™221 or pDONR™/Zeo vector sequence are marked.

---

M13 Forward (−20) priming site

531  GACGTTGTAA AACGACGGCC AGTCCTTAAGC TCGGGCCCCA AATAATGATT TTATTTTGAC AGCCCCGGGT TTATTACTAA AATAAAACTG

591  TGATAGTGAC CTGTTCGGTG CAACACATTTG ATGAGCAATG CTTTTTATA ATG CCA ACT ACTATCAGTT GAACAGCAAC GTTGTGTGAC TACTCAGTTAC GAAAAAATAT TAC GGT TGA

651  TAG TAC AAA AAA GCA GGC TNN --- --- --- NAC CCA GCT TGC TTG TAC AAA

650  AAG ATG TTT TTT CGT CCG ANN --- --- --- NTG GGT CCA AAG AAC ATG TTT

2906  GTT GGC ATT ATAAAGAAAGC ATTTGTTTGC AAGCAACAGG TCACCATCAG CAA CCG TAA ATATCTTTGC TAACGAATAG TTAAACAACG TTGCTTGTCG AGTGATAGTC

2965  TCAAAATAAA ATGATATTTC GCCATCCAGC TGATATCCCC CTTAAGTGAGT CGTATTACAT AGTTTTATTG TAGGATAAAGC CCGTATGTCG

---

M13 Reverse priming site

3025  GTTCATAGCT GTTT CCTGGGC AGCTCTGGCC CGTGCTCAA AATCTCTGAT GTTACATTGC
Appendix

Recipes

Low Salt LB Medium with Zeocin™

10 g Tryptone
5 g NaCl
5 g Yeast Extract

1. Combine the dry reagents above and add deionized, distilled water to 950 mL. Adjust the pH to 7.5 with 5 M NaOH. Bring the volume up to 1 liter. For plates, add 15 g/L agar before autoclaving.

2. Autoclave on liquid cycle at 15 lbs/sq. in. and 121°C for 20 minutes.

3. Thaw Zeocin™ on ice and vortex before removing an aliquot.

4. Allow the medium to cool to at least 55°C before adding the Zeocin™ to 50 μg/mL final concentration.

5. Store plates at 4°C in the dark. Plates containing Zeocin™ are stable for 1–2 weeks.
Zeocin™ Selective Antibiotic

Introduction

Zeocin™ selective antibiotic is a member of the bleomycin/phleomycin family of antibiotics isolated from *Streptomyces*. It shows strong toxicity against bacteria, fungi, plants and mammalian cell lines (Calmels et al., 1991; Drocourt et al., 1990; Gatignol et al., 1987; Mulsant et al., 1988; Perez et al., 1989).

A Zeocin™ resistance protein has been isolated and characterized (Calmels et al., 1991; Drocourt et al., 1990). This 13,665 Da protein, the product of the *Shble* gene (*Streptoalloteichus hindustanus* bleomycin gene), binds stoichiometrically to Zeocin™ selective antibiotic and inhibits its DNA strand cleavage activity. Expression of this protein in eukaryotic and prokaryotic hosts confers resistance to Zeocin™ selective antibiotic.

Molecular weight, Formula, and Structure

The formula for Zeocin™ is C_{55}H_{86}O_{21}N_{20}S_{2}Cu-HCl and the molecular weight is 1527.5. The structure of Zeocin™ is:

![Zeocin™ structure](image)

Handling Zeocin™ selective antibiotic

- High ionic strength and acidity or basicity inhibit the activity of Zeocin™ selective antibiotic. Therefore, we recommend that you reduce the salt in bacterial medium and adjust the pH to 7.5 to keep the drug active (see page 12 for a recipe).
- Store Zeocin™ selective antibiotic at −20°C and thaw on ice before use.
- Zeocin™ selective antibiotic is light sensitive. Store the drug and plates or medium containing the drug in the dark.
- Wear gloves, a laboratory coat, and safety glasses when handling Zeocin™-containing solutions.
- Do not ingest or inhale solutions containing the drug.
Map and Features of pDONR™ 221 and pDONR™/Zeo

The following map shows the elements of pDONR™221 and pDONR™/Zeo. The complete sequences of pDONR™221 and pDONR™/Zeo are available from www.lifetechnologies.com or by contacting Technical Support (page 17).

---

Comments for:

<table>
<thead>
<tr>
<th></th>
<th>pDONR™221 4761 nucleotides</th>
<th>pDONR™/Zeo 4291 nucleotides</th>
</tr>
</thead>
<tbody>
<tr>
<td>rmB T2 transcription termination sequence (c):</td>
<td>268-295</td>
<td>268-295</td>
</tr>
<tr>
<td>rmB T1 transcription termination sequence (c):</td>
<td>427-470</td>
<td>427-470</td>
</tr>
<tr>
<td>M13 Forward (-20) priming site:</td>
<td>537-552</td>
<td>537-552</td>
</tr>
<tr>
<td>atrP1:</td>
<td>570-801</td>
<td>570-801</td>
</tr>
<tr>
<td>ccdB gene (c):</td>
<td>1197-1502</td>
<td>1197-1502</td>
</tr>
<tr>
<td>Chloramphenicol resistance gene (c):</td>
<td>1825-2505</td>
<td>1847-2506</td>
</tr>
<tr>
<td>atrP2 (c):</td>
<td>2753-2984</td>
<td>2754-2985</td>
</tr>
<tr>
<td>M13 Reverse priming site:</td>
<td>3026-3042</td>
<td>3027-3043</td>
</tr>
<tr>
<td>Kanamycin resistance gene:</td>
<td>3155-3964</td>
<td>---</td>
</tr>
<tr>
<td>EM7 promoter (c):</td>
<td>---</td>
<td>3486-3552</td>
</tr>
<tr>
<td>Zeocin resistance gene (c):</td>
<td>---</td>
<td>3111-3485</td>
</tr>
<tr>
<td>pUC origin:</td>
<td>4085-4758</td>
<td>3615-4288</td>
</tr>
</tbody>
</table>

(c) = complementary strand

Continued on next page
pDONR™221 (4761 bp) and pDONR™/Zeo (4291 bp) contain the following elements. Features have been functionally tested.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>rrnB</em> T1 and T2 transcription terminators</td>
<td>Protects the cloned gene from expression by vector-encoded promoters, thereby reducing possible toxicity (Orosz <em>et al.</em>, 1991)</td>
</tr>
<tr>
<td>M13 Forward (∼20) priming site</td>
<td>Allows sequencing in the sense orientation</td>
</tr>
<tr>
<td><em>attP1</em> and <em>attP2</em> sites</td>
<td>Bacteriophage λ-derived DNA recombination sequences that allow recombinational cloning of the gene of interest from a Gateway® expression clone or <em>attB</em> PCR product (Landy, 1989)</td>
</tr>
<tr>
<td><em>ccdB</em> gene</td>
<td>Allows negative selection of the plasmid</td>
</tr>
<tr>
<td>Chloramphenicol resistance gene (Cm&lt;sup&gt;R&lt;/sup&gt;)</td>
<td>Allows counterselection of the plasmid</td>
</tr>
<tr>
<td>T7 promoter/priming site</td>
<td>Allows <em>in vitro</em> transcription and sequencing in the anti-sense orientation</td>
</tr>
<tr>
<td>M13 Reverse priming site</td>
<td>Allows sequencing in the anti-sense orientation</td>
</tr>
<tr>
<td>Kanamycin resistance gene (<em>pDONR™221</em> only)</td>
<td>Allows selection of the plasmid in <em>E. coli</em></td>
</tr>
<tr>
<td>EM7 promoter (<em>pDONR™/Zeo</em> only)</td>
<td>Allows expression of the Zeocin™ resistance gene in <em>E. coli</em>.</td>
</tr>
<tr>
<td>Zeocin™ resistance gene (<em>pDONR™/Zeo</em> only)</td>
<td>Allows selection of the plasmid in <em>E. coli</em></td>
</tr>
<tr>
<td>pUC origin</td>
<td>Allows high-copy replication and maintenance in <em>E. coli</em></td>
</tr>
</tbody>
</table>
# Accessory Products

Additional products that may be used with the Gateway® pDONR™ vectors are available. Ordering information is provided below.

<table>
<thead>
<tr>
<th>Product</th>
<th>Amount</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gateway® BP Clonase® II Enzyme Mix</td>
<td>20 reactions</td>
<td>11789-020</td>
</tr>
<tr>
<td></td>
<td>100 reactions</td>
<td>11789-100</td>
</tr>
<tr>
<td>One Shot® <em>ccd</em>B Survival™ 2 T1&lt;sup&gt;R&lt;/sup&gt;</td>
<td>5 × 0.2 mL</td>
<td>A10460</td>
</tr>
<tr>
<td>Chemically Competent Cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One Shot® TOP10 Chemically Competent Cells</td>
<td>10 reactions</td>
<td>C4040-10</td>
</tr>
<tr>
<td></td>
<td>20 reactions</td>
<td>C4040-03</td>
</tr>
<tr>
<td>One Shot® TOP10 Electrocompetent Cells</td>
<td>10 reactions</td>
<td>C4040-50</td>
</tr>
<tr>
<td></td>
<td>20 reactions</td>
<td>C4040-52</td>
</tr>
<tr>
<td>One Shot® OmniMAX™ 2 T1&lt;sup&gt;R&lt;/sup&gt; Chemically</td>
<td>20 reactions</td>
<td>C8540-03</td>
</tr>
<tr>
<td>Competent Cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Library Efficiency® DH5α™ Competent Cells</td>
<td>5 × 0.2 mL</td>
<td>18263-012</td>
</tr>
<tr>
<td>Kanamycin Sulfate</td>
<td>5 g</td>
<td>11815-024</td>
</tr>
<tr>
<td>Zeocin™ Selection Reagent</td>
<td>1 g</td>
<td>R250-01</td>
</tr>
<tr>
<td></td>
<td>5 g</td>
<td>R250-05</td>
</tr>
<tr>
<td>PureLink® HQ Mini Plasmid DNA Purification Kit</td>
<td>100 preps</td>
<td>K2100-01</td>
</tr>
<tr>
<td>PCR SuperMix High Fidelity</td>
<td>100 reactions</td>
<td>10790-020</td>
</tr>
</tbody>
</table>
## Technical Support

### Obtaining support
For the latest services and support information for all locations, go to [www.lifetechnologies.com/support](http://www.lifetechnologies.com/support).

At the website, you can:
- Access worldwide telephone and fax numbers to contact Technical Support and Sales facilities
- Search through frequently asked questions (FAQs)
- Submit a question directly to Technical Support ([techsupport@lifetech.com](mailto:techsupport@lifetech.com))
- Search for user documents, Safety Data Sheets (SDSs), vector maps and sequences, application notes, formulations, handbooks, certificates of analysis, citations, and other product support documents
- Obtain information about customer training
- Download software updates and patches

### Safety Data Sheets (SDS)
Safety Data Sheets (SDSs) are available at [www.lifetechnologies.com/support](http://www.lifetechnologies.com/support).

### Certificate of Analysis
The Certificate of Analysis provides detailed quality control and product qualification information for each product. Certificates of Analysis are available on our website. Go to [www.lifetechnologies.com/support](http://www.lifetechnologies.com/support) and search for the Certificate of Analysis by product lot number, which is printed on the box.

### Limited Product Warranty
Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies’ General Terms and Conditions of Sale found on Life Technologies’ website at [www.lifetechnologies.com/termsandconditions](http://www.lifetechnologies.com/termsandconditions). If you have any questions, please contact Life Technologies at [www.lifetechnologies.com/support](http://www.lifetechnologies.com/support).
Limited Use Label License No. 19: Gateway® Cloning Products

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications, or to use this product with any recombination sites other than those purchased from Life Technologies Corporation or its authorized distributor.

The right to use methods claimed in the foregoing patents or patent applications with this product for research purposes only can only be acquired by the use of Clonase® purchased from Life Technologies Corporation or its authorized distributors. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Notwithstanding the preceding, any buyer who is employed in an academic or government institution may transfer materials made with this product to a third party who has a license from Life Technologies under the patents identified above to distribute such materials. Transfer of such materials and/or information to collaborators does not convey rights to practice any methods claimed in the foregoing patents or patent applications. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.

Continued on next page
Life Technologies Corporation will not assert a claim against
the buyer of infringement of the above patents based upon
the manufacture, use or sale of a therapeutic, clinical
diagnostic, vaccine or prophylactic product developed in
research by the buyer in which this product or its
components was employed, provided that none of (i) this
product, (ii) any of its components, or (iii) a method claim of
the foregoing patents, was used in the manufacture of such
product. Life Technologies Corporation will not assert a
claim against the buyer of infringement of the above patents
based upon the use of this product to manufacture a protein
for sale, provided that no method claim in the above patents
was used in the manufacture of such protein. If the
purchaser is not willing to accept the limitations of this
limited use statement, Life Technologies is willing to accept
return of the product with a full refund. For information on
purchasing a license to use this product for purposes other
than those permitted above, contact
outlicensing@lifetech.com or Out Licensing, Life
Technologies, 5791 Van Allen Way, Carlsbad, California
92008.

ccdB selection technology is described in Bernard et al.,
"Positive Selection Vectors Using the F Plasmid ccdB Killer
Gene" Gene 148 (1994) 71-74. The purchase of this product
conveys to the buyer the non-transferable right to use the
purchased amount of the product and components of the
product in research conducted by the buyer (whether the
buyer is an academic or for-profit entity). For licensing
information for use in other than research, please contact:
outlicensing@lifetech.com or Out Licensing, Life
Technologies, 5791 Van Allen Way, Carlsbad, California
92008.
Limited Use Label License: Research Use Only

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial services of any kind, including, without limitation, reporting the results of purchaser’s activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

Gateway® Clone Distribution Policy

For additional information about Invitrogen’s policy for the use and distribution of Gateway® clones, see the section entitled Gateway® Clone Distribution Policy, page 21.
# Gateway® Clone Distribution Policy

## Introduction
The information supplied in this section is intended to provide clarity concerning Life Technologies’ policy for the use and distribution of cloned nucleic acid fragments, including open reading frames, created using Life Technologies commercially available Gateway® Technology.

## Gateway® Entry Clones
Life Technologies understands that Gateway® entry clones, containing \texttt{attL1} and \texttt{attL2} sites, may be generated by academic and government researchers for the purpose of scientific research. Life Technologies agrees that such clones may be distributed for scientific research by non-profit organizations and by for-profit organizations without royalty payment to Life Technologies.

## Gateway® Expression Clones
Life Technologies also understands that Gateway® expression clones, containing \texttt{attB1} and \texttt{attB2} sites, may be generated by academic and government researchers for the purpose of scientific research. Life Technologies agrees that such clones may be distributed for scientific research by academic and government organizations without royalty payment to Life Technologies. Organizations other than academia and government may also distribute such Gateway® expression clones for a nominal fee ($10 per clone) payable to Life Technologies.

## Additional Terms and Conditions
We would ask that such distributors of Gateway® entry and expression clones indicate that such clones may be used only for research purposes, that such clones incorporate the Gateway® Technology, and that the purchase of Gateway® Clonase® from Life Technologies is required for carrying out the Gateway® recombinational cloning reaction. This should allow researchers to readily identify Gateway® containing clones and facilitate their use of this powerful technology in their research. Use of Life Technologies’ Gateway® Technology, including Gateway® clones, for purposes other than scientific research may require a license and questions concerning such commercial use should be directed to outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.
References


©2012 Life Technologies Corporation. All rights reserved.

The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

Zeocin is a trademark of Cayla, SA.

LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF.